Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

SHANGHAI, July 2, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to...

Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases

Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases

CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a strategic collaboration with Lonza to...

METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager

METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager

HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S....

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...

Tulip Innovation and Sunwoda Enter Patent License Agreement

Tulip Innovation and Sunwoda Enter Patent License Agreement

BUDAPEST, Hungary and SHENZHEN, China, June 11, 2026 /PRNewswire/ -- Sunwoda Electronic (Sunwoda), a leading global provider of lithium-ion battery technologies and solutions, and Tulip Innovation (Tulip), the licensing agent for lithium-ion battery...

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for...

Herbalgy Trophy & "Goal-Getter Giveaway" - A Triumphant Return

Herbalgy Trophy & "Goal-Getter Giveaway" - A Triumphant Return

Spend HK$180 Unlocks Your Shot at Over HK$1M in Match Tickets – 1,000 Tickets to Chelsea FC vs. Juventus at Kai Tak Buy More, Enter More HONG KONG, May 15, 2026 /PRNewswire/ -- Football fans can now experience the thrill of Chelsea FC vs Juventus...

Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development

Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development

SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo...

Church's Texas Chicken® and Texas Chicken™ Enter China with Landmark 600-Restaurant Agreement

Church's Texas Chicken® and Texas Chicken™ Enter China with Landmark 600-Restaurant Agreement

China Marks the Brand's 27th International Market, With First Shanghai Location Opening Summer 2026 ATLANTA, April 13, 2026 /PRNewswire/ -- Church's Texas Chicken ® and Texas Chicken ™, one of the largest quick-service chicken restaurant brands in...

AMTD IDEA Group's Controlling Shareholder, Directors and Executive Officers Enter into Voluntary Lock-up on Holdings

AMTD IDEA Group's Controlling Shareholder, Directors and Executive Officers Enter into Voluntary Lock-up on Holdings

PARIS, NEW YORK and SINGAPORE, April 8, 2026 /PRNewswire/ -- AMTD IDEA Group ("AMTD IDEA Group") (NYSE: AMTD; SGX: HKB), a NYSE and SGX-ST dual-listed company and a subsidiary of AMTD Group Inc. ("AMTD Group"), today announced that AMTD Group and...

  • 1
  • 2
  • 3
  • 4
  • menu
    menu